Text Size A A A

Sun Pharma In The News

Tell a Friend Print Home » Media » Sun Pharma In The News

US court rules in favour of Sun Pharma in patent case

 

Sun Phar­maceutical Industries on Wednesday said that the US Supreme Court has given a favourable verdict in its pat­ent case against Novo Nordisk over generic Prandin tablets used for treating diabetes.
 
US Supreme Court has ruled in favour of the com­pany's subsidiary, Caraco Pharmaceutical Laboratories, in its patent litigation against Novo Nordisk over Caraco's generic version of prandin, repaglinide tablets, Sun Pharma said in a statement.
 
"The Supreme Court, in a unanimous opinion, con­cluded that Caraco can seek correction of Novo Nordisk's inaccurate use code regarding the combination use of repaglinide and metformin for the treatment of type n diabetes," it added.
 
The judgement has said, "The text and context of the provision demonstrate that a generic company can employ the counterclaim to challenge a brand's overbroad use code. We accordingly hold that Caraco may bring a counterclaim seeking to 'correct' Novos use code."
 
Prandin is a registered trademark of Denmark-based drug firm Novo Nordisk.
 
The decision will help all generic companies prevent brand companies from mis­representing their patents to the United States Food and Drug Administration (usfda) and improperly delaying or preventing generic companies from marketing their drugs, Sun Pharma said. Caraco's abbreviated new drug application (anda) for generic Prandin is still await­ing approval by the usfda, it added.
 
US had earlier alleged that Sun Pharma violated manufacturing standards
 
"Prandin has annual sales of approximately $230 million in the US," Sun Pharma said.
 
A separate appeal concern­ing the validity of patents for Prandjn is pending before the Court of Appeals for the Federal Circuit after a lower court ruled in favour of Caraco, it added.
 
Scrips of Sun Pharma were trading at Rs 96.50 apiece in the afternoon on the bse, up 2.11 per cent from its previous close. US authorities had siezed all medicines produced by Caraco at its Detroit facilities in 2009, citing repeated violations of manufac­turing standards. The generic drug maker subsequently signed a consent decree. It agreed with US health regu­lators to resume manufacturing operations at Detroit only after receiving approval from independent experts and the usfda.